Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib + Alisertib or Sapanisertib for Osimertinib-Resistant EGFR Mutant NSCLC
NCT04479306Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2020
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Arm A (osimertinib, alisertib) with Arm B (osimertinib, sapanisertib) (2 arms). Primary endpoints: Recommended Phase 2 Dose of osimertinib and alisertib combination, Recommended Phase 2 Dose of osimertinib and sapanisertib combination up to 30 days and 2 more. Started Jun 2020; status: completed.
02
Drugs
alisertibsapanisertib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04479306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04479306.